Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

299.20DKK
21 Jun 2018
Change (% chg)

kr.10.65 (+3.69%)
Prev Close
kr.288.55
Open
kr.299.00
Day's High
kr.303.80
Day's Low
kr.296.80
Volume
4,979,323
Avg. Vol
3,103,289
52-wk High
kr.354.80
52-wk Low
kr.260.20

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 20.21 30.95 32.74
EPS (TTM): 15.40 -- --
ROI: 76.65 14.84 14.38
ROE: 84.84 16.34 16.08

Novo's pioneering diabetes pill beats Victoza, Januvia in tests

COPENHAGEN Novo Nordisk's experimental diabetes pill, which it hopes will transform the diabetes market, has proved superior to both Merck & Co's Januvia and its own best-selling injectable treatment Victoza in tests.

21 Jun 2018

Novo Nordisk shares fall after report of layoffs

COPENHAGEN Shares in Novo Nordisk opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets.

08 Jun 2018

Novo Nordisk considers laying-off up to 3,000 staff - Danish paper Borsen

COPENHAGEN, June 7 Novo Nordisk is considering laying-off up to 3,000 staff and dropping its long-term financial targets due to challenging market conditions in the United States, Danish daily Borsen reported Thursday citing unnamed sources.

08 Jun 2018

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON/COPENHAGEN Novo Nordisk said data from a large final-stage study of a pill it hopes will transform the diabetes market proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance.

30 May 2018

Novo Nordisk's oral diabetes drug beats Jardiance in study

LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.

29 May 2018

Factbox: Company deals at risk from U.S. sanctions on Iran

French gas and power group Engie , Polish gas firm PGNiG and German lender DZ Bank were the latest companies on Friday to say that their business dealings with Iran would be affected by the re-imposition of U.S. sanctions.

19 May 2018

FACTBOX-Company deals at risk from U.S. sanctions on Iran

May 18 French gas and power group Engie , Polish gas firm PGNiG and German lender DZ Bank were the latest companies on Friday to say that their business dealings with Iran would be affected by the re-imposition of U.S. sanctions.

18 May 2018

Factbox: Company deals at risk from U.S. sanctions on Iran

French energy company Total said on Wednesday it may pull out of the Iran South Pars 11 (SP11) energy project in light of U.S. President Donald Trump's decision to withdraw from an international nuclear deal and reinstate sanctions on Tehran.

16 May 2018

FACTBOX-Company deals at risk from U.S. sanctions on Iran

May 16 French energy company Total said on Wednesday it may pull out of the Iran South Pars 11 (SP11) energy project in light of U.S. President Donald Trump's decision to withdraw from an international nuclear deal and reinstate sanctions on Tehran.

16 May 2018

FACTBOX-Iran's deals with foreign firms since easing of sanctions in 2015

May 9 President Donald Trump on Tuesday pulled the United States out of the 2015 international nuclear deal with Iran, raising the risk of conflict in the Middle East, upsetting European allies and casting uncertainty over global oil supplies.

09 May 2018

Earnings vs. Estimates